Simone Martins de Castro

Dr. Simone Martins de Castro


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2017 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
CKCristiane Kopacek
Cristiane Kopacek
Simone Martins de CastroSimone Martins de Castro
Simone Martins de Castro
MPMayara Jorgens Prado
Mayara Jorgens Prado
CSClaudia Maria Dornelles da Silva
Claudia Maria Dornelles da Silva
LBLuciana Amorim Beltrão
Luciana Amorim Beltrão
PSPoli Spritzer
Poli Spritzer
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder associated with inborn errors of steroid metabolism. 21-hydroxylase enzyme deficiency occurs in 90 to 95% of all cases of CAH, with accumulation of 17 hydroxyprogesterone (17-OHP). Early diagnosis of CAH based on newborn screening is possible before the development of symptoms and allows proper treatment, correct sex assignment, and reduced mortality rates. This study describes the results obtained in the first year of a public CAH screening program in the state of Rio Grande do Sul, Brazil. We reviewed the screening database in search of babies with suspected CAH, that is, altered birth-weight adjusted 17-OHP values at screening. The following data were analyzed for this population: screening 17-OHP values, retest 17-OHP values, serum 17-OHP values for those with confirmed CAH on retest, maternal and newborn data, and family history of CAH. For the screening program, 17-OHP levels are determined on dried blood spots obtained in filter paper with GSP solid phase time-resolved immunofluorescence. Of 108,409 newborns screened, eight were diagnosed with CAH (four males, four females). The incidence of CAH in the state was 1:13,551. Six cases were identified as classic salt-wasting CAH and two were cases of virilizing CAH. The positive predictive value (PPV) of the initial screening (before diagnostic confirmation) was 1.6%. The overall rate of false positive results was 0.47%. The number of false positive results was higher among newborns with birth weight < 2000 g. The present results support the need for CAH screening by the public health care system in the state, and show that the strategy adopted is adequate. PPV and false positive results were similar to those reported for other states of Brazil with similar ethnic backgrounds.

1 January 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
SBSuzane Dal Bó
Suzane Dal Bó
AFAna Luiza Rodrigues Fragoso
Ana Luiza Rodrigues Fragoso
MFMariela Granero Farias
Mariela Granero Farias
DHDariana Pimentel Gomes Hubner
Dariana Pimentel Gomes Hubner
Simone Martins de CastroSimone Martins de Castro
Simone Martins de Castro
During pregnancy, women are at an increased risk of developing iron-deficiency anemia. The objective of this study was to assess the diagnostic performance of the reticulocyte hemoglobin equivalent (RET-He) in the early detection of iron-deficiency anemia in a group of pregnant women and to establish a reference range for this parameter in a group of control individuals. A total of 60 patients and 130 control subjects were included in the study. Blood samples collected from the subjects were submitted to a complete blood count and a serum ferritin test and the data were analyzed by comparing the groups and ROC curves. The reference range found for the RET-He was between 29.75pg and 38.24pg, with a median of 35pg. The receiver operating characteristic (ROC) curve analysis for the ferritin parameter showed an area under the curve of 0.732 for the RET-He, 0.586 for hemoglobin, 0.551 for the mean corpuscular hemoglobin concentration and 0.482 for the mean corpuscular volume. Early diagnosis of iron deficiency anemia in pregnancy is essential to prevent damage to both maternal and fetal health. The RET-He presents an excellent potential as an auxiliary tool for the diagnosis of iron deficiency in pregnant women.

17 August 2017 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
MPMayara Jorgens Prado
Mayara Jorgens Prado
Simone Martins de CastroSimone Martins de Castro
Simone Martins de Castro
CKCristiane Kopacek
Cristiane Kopacek
MMMaricilda Palandi De Mello
Maricilda Palandi De Mello
TRThaiane Rispoli
Thaiane Rispoli
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti

1 January 2023 in Genetics and Molecular Biology
Verified
Journal Article
Open access
PDF file
ANAlice Brinckmann Oliveira Netto
Alice Brinckmann Oliveira Netto
ABAna Carolina Brusius-Facchin
Ana Carolina Brusius-Facchin
JLJúlia F. Lemos
Júlia F. Lemos
FPFernanda B. Pasetto
Fernanda B. Pasetto
CBCarolina S. Brasil
Carolina S. Brasil
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
Spinal muscular atrophy (SMA) is considered one of the most common autosomal recessive disorders, with an estimated incidence of 1 in 10,000 live births. Testing for SMA has been recommended for inclusion in neonatal screening (NBS) panels since there are several therapies available and there is evidence of greater efficacy when introduced in the pre/early symptomatic phases. In Brazil, the National Neonatal Screening Program tests for six diseases, with a new law issued in 2021 stating that it should incorporate more diseases, including SMA. In the present study, dried blood spot (DBS) samples collected by the Reference Services of Neonatal Screening of RS and SP, to perform the conventional test were also screened for SMA, using real-time PCR, with SALSA MC002 technique. A total of 40,000 samples were analyzed, enabling the identification of four positive cases of SMA, that were confirmed by MLPA. Considering our sampling, Brazil seems to have an incidence comparable to the described in other regions. This work demonstrated that the use of the MC002 technique in samples routinely collected for the conventional NBS program is suitable to screen for SMA in our conditions and can be included in the expansion of the neonatal screening programs.

1 May 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
CKCristiane Kopacek
Cristiane Kopacek
MPMayara Jorgens Prado
Mayara Jorgens Prado
CSClaudia M.D. da Silva
Claudia M.D. da Silva
Simone Martins de CastroSimone Martins de Castro
Simone Martins de Castro
LBLuciana A. Beltrão
Luciana A. Beltrão
PSPoli Spritzer
Poli Spritzer
Objective: To describe the results obtained in a neonatal screening program after its implementation and to assess the clinical and molecular profiles of confirmed and suspicious congenital adrenal hyperplasia cases. Methods: A cross-sectional study was conducted. Newborns with suspected disease due to high 17-hydroxyprogesterone levels and adjusted for birth weight were selected. Classical congenital adrenal hyperplasia (salt-wasting and simple virilizing forms) was diagnosed by an increase in 17-hydroxyprogesterone levels as confirmed in the retest, clinical evaluation, and genotype determined by SNaPshot and multiplex ligation-dependent probe amplification. Results: After 24 months, 15 classic congenital adrenal hyperplasia cases were diagnosed in a total of 217, 965 newborns, with an estimated incidence of 1:14, 531. From 132 patients, seven non-classical and 14 heterozygous patients were screened for CYP21A2 mutations, and 96 patients presented false positives with wild type CYP21A2. On retest, increased 17-hydroxyprogesterone levels were found in classical congenital adrenal hyperplasia patients and showed significant correlation with genotype-related classical genital adrenal hyperplasia. The most frequent mutations were IV52-13A/C >G followed by gene deletion or rearrangement events in the classical form. In non-classical and heterozygous diseases, p.Val282Leu was the most common mutation. Conclusions: The results underscore the effectiveness of congenital adrenal hyperplasia neonatal screening in the public health system and indicate that the adopted strategy was appropriate. The second sample collection along with genotyping of suspected cases helped to properly diagnose both severe and milder cases and delineate them from false positive patients. (C) 2018 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria.

13 July 2016 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
MFMariela Granero Farias
Mariela Granero Farias
SBSuzane Dal Bó
Suzane Dal Bó
Simone Martins de CastroSimone Martins de Castro
Simone Martins de Castro
ASAline Reis da Silva
Aline Reis da Silva
JBJoyce Bonazzoni
Joyce Bonazzoni
SCSergio H. Almeida Martins Costa
Sergio H. Almeida Martins Costa
Accurate detection and quantitation of fetomaternal hemorrhage (FMH) is critical to the obstetric management of rhesus D alloimmunization in Rh-negative pregnant women. The flow cytometry is based on the detection of fetal red blood cells using a monoclonal anti-HbF antibody, and is the method most indicated for this estimation. The objective of this study was to quantify fetal red blood cell levels of pregnant women using flow cytometry. We analyzed 101 peripheral blood samples from Rh-negative and Rh-positive women, whose mean age was 24 years (20–32 years), after vaginal delivery or cesarean section. Our study showed that 53% of pregnant women had fetal red blood cells levels 15.0 mL. Accurate quantitation of fetal red blood cells is necessary to determine the appropriate dose of anti-D (RHD) immunoglobulin to be administered to pregnant or postpartum women.